Heartland Advisors Inc. maintained its stake in TherapeuticsMD Inc (NASDAQ:TXMD) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 600,000 shares of the company’s stock at the end of the third quarter. Heartland Advisors Inc. owned 0.31% of TherapeuticsMD worth $4,086,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. TD Asset Management Inc. raised its stake in TherapeuticsMD by 3.5% in the third quarter. TD Asset Management Inc. now owns 551,300 shares of the company’s stock valued at $3,754,000 after buying an additional 18,400 shares in the last quarter. Sanders Morris Harris Inc. raised its stake in TherapeuticsMD by 18.9% in the third quarter. Sanders Morris Harris Inc. now owns 506,100 shares of the company’s stock valued at $3,446,000 after buying an additional 80,500 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in TherapeuticsMD during the third quarter valued at approximately $2,724,000. UBS Asset Management Americas Inc. raised its stake in TherapeuticsMD by 3.6% in the third quarter. UBS Asset Management Americas Inc. now owns 109,772 shares of the company’s stock valued at $748,000 after buying an additional 3,818 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in TherapeuticsMD by 74.5% in the third quarter. First Trust Advisors LP now owns 90,707 shares of the company’s stock valued at $618,000 after buying an additional 38,723 shares in the last quarter.

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD Inc (NASDAQ:TXMD) traded down 15.46% during trading on Tuesday, hitting $5.74. 17,484,223 shares of the stock traded hands. The company’s 50 day moving average price is $6.27 and its 200-day moving average price is $7.33. TherapeuticsMD Inc has a 52-week low of $4.39 and a 52-week high of $11.26. The stock’s market cap is $1.13 billion.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/29/heartland-advisors-inc-has-4086000-position-in-therapeuticsmd-inc-txmd.html.

TXMD has been the topic of several research analyst reports. Guggenheim reiterated a “buy” rating on shares of TherapeuticsMD in a research report on Tuesday. Jefferies Group initiated coverage on shares of TherapeuticsMD in a research report on Tuesday, November 22nd. They issued a “buy” rating and a $18.00 target price on the stock. Oppenheimer Holdings Inc. initiated coverage on shares of TherapeuticsMD in a research report on Tuesday, November 22nd. They issued an “outperform” rating and a $12.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Thursday, November 24th.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.